A Phase IIb, Open Label, Randomized Controlled Dose Ranging Multi-Center Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Exposure-Response Relationship of Different Doses of Delpazolid in Combination With Bedaquiline Delamanid Moxifloxacin in Adult Subjects With Newly Diagnosed, Uncomplicated, Smear-Positive, Drug-sensitive Pulmonary Tuberculosis
Latest Information Update: 11 Apr 2024
At a glance
- Drugs Bedaquiline (Primary) ; Delamanid (Primary) ; Delpazolid (Primary) ; Moxifloxacin (Primary) ; Isoniazid; Rifampicin
- Indications Pulmonary tuberculosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms DECODE; PanACEA-DECODE
- Sponsors LegoChem Biosciences
- 20 Feb 2024 Status changed from active, no longer recruiting to completed.
- 06 Jun 2023 Trial design, published in the Trials
- 13 Sep 2022 Planned End Date changed from 30 Jan 2023 to 30 Mar 2024.